Request for Proposals: Pfizer Quality Improvement Program

Pfizer invites proposals for its Quality Improvement Request for Proposals (RFP), aiming to enhance care for adult patients infected by Metallo-β-Lactamase-producing Enterobacterales (MBL-CRE) or Stenotrophomonas maltophilia. This initiative is part of Pfizer’s Competitive Grant Program using an internal review process. Proposals should focus on developing interventions that improve local care pathways, from early risk identification to treatment and outcome evaluation. The submission deadline is 17 November 2026. The RFP seeks proposals to standardize and enhance care pathways for adult patients with infections caused by MBL-producing Enterobacterales and Stenotrophomonas maltophilia. The goal is to improve patient management through early risk identification, diagnostic optimization, and appropriate treatment evaluation. Eligible applicants include organizations such as healthcare institutions, professional schools, and government agencies with a focus on healthcare improvement. Individual applicants or medical practice groups are not eligible. Applicants from India must possess a valid Foreign Contribution Regulation Act (FCRA) certificate. Collaborations within and between institutions are encouraged. Addressing the complex challenge of infections caused by MBL-producing Enterobacterales or Stenotrophomonas maltophilia is crucial due to their significant clinical and economic burden. The initiative aims to improve patient care, reduce treatment duration, and enhance hospital data collaboration. Eligible applicants should carefully review the official guidelines and ensure their proposals align with the RFP’s objectives. For further details, consult the Pfizer QI Grants information page and direct any questions to Grant Officer Talita Honorato-Rzeszewicz at [contact details removed]. For more information, visit Pfizer.